Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: A single institution analysis

Journal of B.U.ON.

Volumn 19, Issue 1, 2014, Pages 83-90

  Cvetanovic, Ana ^a   Vrbic, Svetislav ^a,b   Filipovic, Sladjana ^a,b   Pejcic, Ivica ^a,b   Milenkovic, Dusan ^a   Zivkovic, Nikola ^b   Kostic, Milos ^b   Petkovic, Ivan ^a  

^a Clinic of Oncology Clinical Centre Nis   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

Author keywords

Cetuximab; Clinical benefit; Metastatic colorectal cancer; Skin toxicity

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BODY SURFACE; BULLOUS DERMATITIS; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; DESQUAMATION; DISEASE CONTROL; DISEASE COURSE; DNA EXTRACTION; ERYTHEMA; ERYTHRODERMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MUTATION; PAPULAR RASH; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; PYODERMA GANGRENOSUM; SKIN TOXICITY; THERAPY; TREATMENT RESPONSE; VESICULAR RASH; WILD TYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SKIN ABNORMALITIES;

EID: 84898849466     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Petrelli F, Borgonovo K, Cabiddu M et al. Cetuximab and panitumumab in KRAS wild- type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011;26:823-833.
2. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biol 2000;21:105-115. (Pubitemid 30114656)
3. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. (Pubitemid 38944402)
4. De Roock W, Piessavaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-515. (Pubitemid 351325672)
5. Heinemann V, Stintzing S, Kircher T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009;35:262-271.
6. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of ras mutation in human colorectal cancer. Nature 1987;327:293-297. (Pubitemid 17075079)
7. Finkeistein SD, Sayeqh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993;71:3827-3838. (Pubitemid 23172957)
8. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
9. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC:Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
10. Freemen DJ, Juan T, Reiner M et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008:7;184-190. (Pubitemid 351758148)
11. Van Cutsem E, Mayer R, Gold P et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer 2004;2(Suppl) :85-86 (abstr 279).
12. Saltz L, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208. (Pubitemid 41079832)
13. Lenz HJ, Van Custem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921. (Pubitemid 46630920)
14. Van Custem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
15. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first-line treatment in metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
16. Pérez-Soler R, Van Cutsem E. Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology 2007;21 (Suppl 5) :10-16.
17. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379. (Pubitemid 351171687)
18. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil and leucovorin as firstline treatment for metastatic colorectal cancer: update analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
19. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169. (Pubitemid 46625066)
20. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
21. Karapetis C, Khambata-Ford S, Jonker D et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
22. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-1145. (Pubitemid 47587019)
23. Ocvirk J, Brodowicz T, Wrba F et al. Cetuximab plus FOLFOX 6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastrenterol 2010;16:3133-3143.
24. Benvenuti S, Sartore-Bianchi A, Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-2648. (Pubitemid 46548951)
25. Maughan S, Adams R, Smith C et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-2114.
26. Saltz L, Kies MS, Abbruzzese J, Azarnia N, Needle MN. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Prog Proc Am Soc Clin Oncol 2003;22:204 (abstr 817).
27. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247. (Pubitemid 41103678)
28. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of head and neck. N Engl J Med 2006;354:567-578. (Pubitemid 43209104)
29. Clark GM, Perez-Soler R, Siu L et al. Rash severity is predictive of increased survival with erlotinib HCI. Proc Am Soc Clin Oncol 2003;22:196 (abstr 786).
30. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment for the colorectal cancer. N Engl J Med 2007;357:2040-2048.
31. Chung KY, Shia J, Kemeni NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810. (Pubitemid 46211358)
32. Zhang W, Gordon M, Press OA et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics 2006;16:475-483. (Pubitemid 43922345)
33. Tejpar S, Peeters M, Humblet Y et al. Phase I/II study of cetuximab dose-escalations in patients with metastatic colorectal cancer (mCRC) with no slight skin reaction on cetuximab standard dose treatment (EV-EREST): Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007;25 (Suppl): abstr 4037.
34. Schrag D. The price tag on progress:Chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-319. (Pubitemid 38944397)